{"id":"NCT01339559","sponsor":"UCB BIOSCIENCES, Inc.","briefTitle":"Brivaracetam Safety and Efficacy Follow-up Study in Subjects With Epilepsy","officialTitle":"An Open-label, Multicenter, Follow-up Study to Evaluate the Long-term Safety and Efficacy of Brivaracetam Used as Adjunctive Treatment in Subjects Aged 16 Years or Older With Epilepsy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-05-11","primaryCompletion":"2019-04-18","completion":"2019-04-18","firstPosted":"2011-04-20","resultsPosted":"2020-06-04","lastUpdate":"2021-08-17"},"enrollment":767,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Epilepsy"],"interventions":[{"type":"DRUG","name":"Brivaracetam","otherNames":["UCB34714"]}],"arms":[{"label":"Brivaracetam","type":"EXPERIMENTAL"}],"summary":"This is a Phase 3, open label, long term follow-up (LTFU), multicenter, noncomparative, and single arm study of brivaracetam (BRV).","primaryOutcome":{"measure":"Percentage of Participants With at Least One Treatment-Emergent Adverse Event (TEAE)","timeFrame":"From Entry Visit (Month 0) until the Last Visit (up to 84 months)","effectByArm":[{"arm":"Brivaracetam (SS)","deltaMin":83.9,"sd":null}],"pValues":[]},"eligibility":{"minAge":"16 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":7},"locations":{"siteCount":184,"countries":["United States","Austria","Belgium","Brazil","Bulgaria","Canada","Czechia","Estonia","Finland","France","Germany","Hong Kong","Hungary","India","Italy","Japan","Latvia","Lithuania","Mexico","Netherlands","Poland","Puerto Rico","Russia","South Korea","Spain","Sweden","Taiwan","United Kingdom"]},"refs":{"pmids":["34218211","36435010","26899665","26471380"],"seeAlso":["http://www.briviact.com/briviact-PI.pdf?v=1479491757","http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm"]},"adverseEventsSummary":{"seriousAny":{"events":140,"n":766},"commonTop":["Headache","Dizziness","Somnolence","Nasopharyngitis","Fatigue"]}}